Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.59 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548070 | 0.91 | CXCR4 (0.62) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL674945 | 0.89 | CXCR4 (0.75) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL12203046 | 0.87 | CXCR4 (0.77) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL14144707 | 0.87 | CXCR4 (0.77) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL675084 | 0.87 | CXCR4 (0.67) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL1259323 | 0.87 | CXCR4 (0.67) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL17929341 | 0.87 | CXCR4 (0.72) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| Bromide SCHEMBL5675524 | 0.86 | CXCR4 (0.71) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL6237364 | 0.86 | SIGMAR1 (0.61) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL674847 | 0.86 | CXCR4 (0.65) | CXCR4TDP1MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3337519-B1 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | SOUTHWESTERN OKLAHOMA STATE UNIV (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210179606-A1 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | SOUTHWESTERN OKLAHOMA STATE UNIV (US) | 2021-06-17 | — | — | US | disclosed |
| US-10927108-B2 | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same | SOUTHWESTERN OKLAHOMA STATE UNIVERSITY (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2017030728-A1 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | SOUTHWESTERN OKLAHOMA STATE UNIVERSITY (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927108-B2 | Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same | HCCS, CYCS, CYC1 | CXCR4 2237/4885TDP1 2554/4885MEN1 419/4885 |
| US-20210179606-A1 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | HCCS, CYCS, CYC1 | CXCR4 2237/4885TDP1 2554/4885MEN1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.